Literature DB >> 27784745

Mutational Landscape and Gene Expression Patterns in Adult Acute Myeloid Leukemias with Monosomy 7 as a Sole Abnormality.

Ann-Kathrin Eisfeld1, Jessica Kohlschmidt2,3, Krzysztof Mrózek2, Stefano Volinia4, James S Blachly5, Deedra Nicolet2,3, Christopher Oakes5, Karl Kroll5, Shelley Orwick5, Andrew J Carroll6, Richard M Stone7, John C Byrd5, Albert de la Chapelle2, Clara D Bloomfield1.   

Abstract

Monosomy of chromosome 7 is the most frequent autosomal monosomy in acute myeloid leukemia (AML), where it associates with poor clinical outcomes. However, molecular features associated with this sole monosomy subtype (-7 AML), which may give insights into the basis for its poor prognosis, have not been characterized. In this study, we analyzed 36 cases of -7 AML for mutations in 81 leukemia/cancer-associated genes using a customized targeted next-generation sequencing panel (Miseq). Global gene and miRNA expression profiles were also determined using paired RNA and small RNA sequencing data. Notably, gene mutations were detected in all the major AML-associated functional groups, which include activated signaling, chromatin remodeling, cohesin complex, methylation, NPM1, spliceosome, transcription factors, and tumor suppressors. Gene mutations in the chromatin remodeling groups were relatively more frequent in patients <60 years of age, who also had less mutations in the methylation and spliceosome groups compared with patients ≥60 years of age. Novel recurrent mutational events in AML were identified in the SMARCA2 gene. In patients ≥60 years of age, the presence of spliceosome mutations associated with a lower complete remission rate (P = 0.03). RNA sequencing revealed distinct gene and miRNA expression patterns between the sole -7 and non -7 AML cases, with reduced expression, as expected, of many genes and miRNAs mapped to chromosome 7, and overexpression of ID1, MECOM, and PTPRM, among others. Overall, our findings illuminate a number of molecular features of the underlying aggressive pathobiology in -7 AML patients. Cancer Res; 77(1); 207-18. ©2016 AACR. ©2016 American Association for Cancer Research.

Entities:  

Mesh:

Year:  2016        PMID: 27784745      PMCID: PMC5215102          DOI: 10.1158/0008-5472.CAN-16-1386

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  49 in total

1.  Genomic structure of the PIK3CG gene on chromosome band 7q22 and evaluation as a candidate myeloid tumor suppressor.

Authors:  Christian P Kratz; Brooke M Emerling; Jeannette Bonifas; Winfred Wang; Eric D Green; Michelle M Le Beau; Kevin M Shannon
Journal:  Blood       Date:  2002-01-01       Impact factor: 22.113

2.  Loss of Chromosome 8p Governs Tumor Progression and Drug Response by Altering Lipid Metabolism.

Authors:  Yanyan Cai; Jonathan Crowther; Tibor Pastor; Layka Abbasi Asbagh; Maria Francesca Baietti; Magdalena De Troyer; Iria Vazquez; Ali Talebi; Fabrizio Renzi; Jonas Dehairs; Johannes V Swinnen; Anna A Sablina
Journal:  Cancer Cell       Date:  2016-05-09       Impact factor: 31.743

3.  Prognostic significance of, and gene and microRNA expression signatures associated with, CEBPA mutations in cytogenetically normal acute myeloid leukemia with high-risk molecular features: a Cancer and Leukemia Group B Study.

Authors:  Guido Marcucci; Kati Maharry; Michael D Radmacher; Krzysztof Mrózek; Tamara Vukosavljevic; Peter Paschka; Susan P Whitman; Christian Langer; Claudia D Baldus; Chang-Gong Liu; Amy S Ruppert; Bayard L Powell; Andrew J Carroll; Michael A Caligiuri; Jonathan E Kolitz; Richard A Larson; Clara D Bloomfield
Journal:  J Clin Oncol       Date:  2008-09-22       Impact factor: 44.544

4.  Cytogenetic and molecular delineation of a region of chromosome 7 commonly deleted in malignant myeloid diseases.

Authors:  M M Le Beau; R Espinosa; E M Davis; J D Eisenbart; R A Larson; E D Green
Journal:  Blood       Date:  1996-09-15       Impact factor: 22.113

Review 5.  Mutations predisposing to hereditary nonpolyposis colorectal cancer.

Authors:  P Peltomäki; A de la Chapelle
Journal:  Adv Cancer Res       Date:  1997       Impact factor: 6.242

6.  Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia.

Authors:  Xose S Puente; Magda Pinyol; Víctor Quesada; Laura Conde; Gonzalo R Ordóñez; Neus Villamor; Georgia Escaramis; Pedro Jares; Sílvia Beà; Marcos González-Díaz; Laia Bassaganyas; Tycho Baumann; Manel Juan; Mónica López-Guerra; Dolors Colomer; José M C Tubío; Cristina López; Alba Navarro; Cristian Tornador; Marta Aymerich; María Rozman; Jesús M Hernández; Diana A Puente; José M P Freije; Gloria Velasco; Ana Gutiérrez-Fernández; Dolors Costa; Anna Carrió; Sara Guijarro; Anna Enjuanes; Lluís Hernández; Jordi Yagüe; Pilar Nicolás; Carlos M Romeo-Casabona; Heinz Himmelbauer; Ester Castillo; Juliane C Dohm; Silvia de Sanjosé; Miguel A Piris; Enrique de Alava; Jesús San Miguel; Romina Royo; Josep L Gelpí; David Torrents; Modesto Orozco; David G Pisano; Alfonso Valencia; Roderic Guigó; Mónica Bayés; Simon Heath; Marta Gut; Peter Klatt; John Marshall; Keiran Raine; Lucy A Stebbings; P Andrew Futreal; Michael R Stratton; Peter J Campbell; Ivo Gut; Armando López-Guillermo; Xavier Estivill; Emili Montserrat; Carlos López-Otín; Elías Campo
Journal:  Nature       Date:  2011-06-05       Impact factor: 49.962

7.  The spectrum of somatic mutations in high-risk acute myeloid leukaemia with -7/del(7q).

Authors:  Megan E McNerney; Christopher D Brown; April L Peterson; Mekhala Banerjee; Richard A Larson; John Anastasi; Michelle M Le Beau; Kevin P White
Journal:  Br J Haematol       Date:  2014-06-13       Impact factor: 6.998

8.  CUX1 is a haploinsufficient tumor suppressor gene on chromosome 7 frequently inactivated in acute myeloid leukemia.

Authors:  Megan E McNerney; Christopher D Brown; Xiaoyue Wang; Elizabeth T Bartom; Subhradip Karmakar; Chaitanya Bandlamudi; Shan Yu; Jinkyung Ko; Barry P Sandall; Thomas Stricker; John Anastasi; Robert L Grossman; John M Cunningham; Michelle M Le Beau; Kevin P White
Journal:  Blood       Date:  2012-12-03       Impact factor: 22.113

9.  Id1 is a common downstream target of oncogenic tyrosine kinases in leukemic cells.

Authors:  Winnie F Tam; Ting-Lei Gu; Jing Chen; Benjamin H Lee; Lars Bullinger; Stefan Fröhling; Andrew Wang; Stefano Monti; Todd R Golub; D Gary Gilliland
Journal:  Blood       Date:  2008-06-17       Impact factor: 22.113

10.  Mutational spectrum of myeloid malignancies with inv(3)/t(3;3) reveals a predominant involvement of RAS/RTK signaling pathways.

Authors:  Stefan Gröschel; Mathijs A Sanders; Remco Hoogenboezem; Annelieke Zeilemaker; Marije Havermans; Claudia Erpelinck; Eric M J Bindels; H Berna Beverloo; Hartmut Döhner; Bob Löwenberg; Konstanze Döhner; Ruud Delwel; Peter J M Valk
Journal:  Blood       Date:  2014-11-07       Impact factor: 22.113

View more
  9 in total

Review 1.  Not Only Mutations Matter: Molecular Picture of Acute Myeloid Leukemia Emerging from Transcriptome Studies.

Authors:  Luiza Handschuh
Journal:  J Oncol       Date:  2019-07-30       Impact factor: 4.375

2.  Response to letter to the editor of Carcinogenesis by Pira et al., 2017.

Authors:  Nathaniel Rothman; Qing Lan; Martyn T Smith; Roel Vermeulen; Luoping Zhang
Journal:  Carcinogenesis       Date:  2017-12-07       Impact factor: 4.944

3.  Selective targeting of NAMPT by KPT-9274 in acute myeloid leukemia.

Authors:  Shaneice R Mitchell; Karilyn Larkin; Nicole R Grieselhuber; Tzung-Huei Lai; Matthew Cannon; Shelley Orwick; Pratibha Sharma; Yerdanose Asemelash; Pu Zhang; Virginia M Goettl; Larry Beaver; Alice Mims; Vinay K Puduvalli; James S Blachly; Amy Lehman; Bonnie Harrington; Sally Henderson; Justin T Breitbach; Katie E Williams; Shuai Dong; Erkan Baloglu; William Senapedis; Karl Kirschner; Deepa Sampath; Rosa Lapalombella; John C Byrd
Journal:  Blood Adv       Date:  2019-02-12

4.  Large-Scale Identification of Clonal Hematopoiesis and Mutations Recurrent in Blood Cancers.

Authors:  Julie E Feusier; Sasi Arunachalam; Tsewang Tashi; Monika J Baker; Chad VanSant-Webb; Amber Ferdig; Bryan E Welm; Juan L Rodriguez-Flores; Christopher Ours; Lynn B Jorde; Josef T Prchal; Clinton C Mason
Journal:  Blood Cancer Discov       Date:  2021-03-03

5.  Formaldehyde, Hematotoxicity, and Chromosomal Changes-Response.

Authors:  Nathaniel Rothman; Luoping Zhang; Martyn T Smith; Roel Vermeulen; Qing Lan
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2018-01       Impact factor: 4.090

Review 6.  BRM: the core ATPase subunit of SWI/SNF chromatin-remodelling complex-a tumour suppressor or tumour-promoting factor?

Authors:  Iga Jancewicz; Janusz A Siedlecki; Tomasz J Sarnowski; Elzbieta Sarnowska
Journal:  Epigenetics Chromatin       Date:  2019-11-13       Impact factor: 4.954

Review 7.  Inhibitor of DNA binding proteins revealed as orchestrators of steady state, stress and malignant hematopoiesis.

Authors:  Shweta Singh; Tanmoy Sarkar; Brad Jakubison; Stephen Gadomski; Andrew Spradlin; Kristbjorn O Gudmundsson; Jonathan R Keller
Journal:  Front Immunol       Date:  2022-08-05       Impact factor: 8.786

8.  The nomograms for predicting overall and cancer-specific survival in elderly patients with early-stage lung cancer: A population-based study using SEER database.

Authors:  Gen Yu; Xiaozhu Liu; Yunhe Li; Yang Zhang; Ruxin Yan; Lingfeng Zhu; Zhongjian Wang
Journal:  Front Public Health       Date:  2022-09-08

9.  Aneuploid acute myeloid leukemia exhibits a signature of genomic alterations in the cell cycle and protein degradation machinery.

Authors:  Giorgia Simonetti; Antonella Padella; Italo Farìa do Valle; Maria Chiara Fontana; Eugenio Fonzi; Samantha Bruno; Carmen Baldazzi; Viviana Guadagnuolo; Marco Manfrini; Anna Ferrari; Stefania Paolini; Cristina Papayannidis; Giovanni Marconi; Eugenia Franchini; Elisa Zuffa; Maria Antonella Laginestra; Federica Zanotti; Annalisa Astolfi; Ilaria Iacobucci; Simona Bernardi; Marco Sazzini; Elisa Ficarra; Jesus Maria Hernandez; Peter Vandenberghe; Jan Cools; Lars Bullinger; Emanuela Ottaviani; Nicoletta Testoni; Michele Cavo; Torsten Haferlach; Gastone Castellani; Daniel Remondini; Giovanni Martinelli
Journal:  Cancer       Date:  2018-11-27       Impact factor: 6.860

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.